Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Veracyte (VCYT) Equity Average (2016 - 2025)

Historic Equity Average for Veracyte (VCYT) over the last 13 years, with Q3 2025 value amounting to $1.2 billion.

  • Veracyte's Equity Average rose 737.08% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year increase of 737.08%. This contributed to the annual value of $1.1 billion for FY2024, which is 475.47% up from last year.
  • Veracyte's Equity Average amounted to $1.2 billion in Q3 2025, which was up 737.08% from $1.2 billion recorded in Q2 2025.
  • In the past 5 years, Veracyte's Equity Average registered a high of $1.2 billion during Q3 2025, and its lowest value of $697.7 million during Q1 2021.
  • Moreover, its 5-year median value for Equity Average was $1.1 billion (2024), whereas its average is $1.1 billion.
  • Its Equity Average has fluctuated over the past 5 years, first skyrocketed by 32609.29% in 2021, then plummeted by 364.03% in 2022.
  • Quarter analysis of 5 years shows Veracyte's Equity Average stood at $1.1 billion in 2021, then decreased by 3.64% to $1.1 billion in 2022, then dropped by 1.19% to $1.0 billion in 2023, then increased by 12.1% to $1.2 billion in 2024, then increased by 5.39% to $1.2 billion in 2025.
  • Its last three reported values are $1.2 billion in Q3 2025, $1.2 billion for Q2 2025, and $1.2 billion during Q1 2025.